Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.54 |
| ▸ | CA2 | P00918 | 10/20 | 0.54 |
| ▸ | CA9 | Q16790 | 10/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 3/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423204 | 0.86 | PDGFRB (0.61) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2730940 | 0.86 | CA1 (0.53) | CA1CA2CA9CA12CA3 | |
| SCHEMBL446061 | 0.84 | ALDH1A1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL422455 | 0.84 | LPL (0.61) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1284377 | 0.83 | CA1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL706622 | 0.83 | CA1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14942938 | 0.83 | CA1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL441226 | 0.83 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL28900559 | 0.83 | NPC1 (0.54) | CA1CA2CA9CA12CA3 | |
| SCHEMBL443510 | 0.83 | MDM2 (0.56) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4163283-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| WO-2010120996-A1 | 5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120991-A1 | 5, 6, 7, 8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR, PI3, AND HSMG-1 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009143317-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | CA1 4664/4885CA2 3434/4885CA9 2319/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | CA1 4280/4885CA2 2972/4885CA9 2358/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | CA1 4280/4885CA2 2972/4885CA9 2358/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CA1 4825/4885CA2 3009/4885CA9 3373/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | CA1 3342/4885CA2 1567/4885CA9 643/4885 |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | CA1 4664/4885CA2 3434/4885CA9 2319/4885 |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | BTK, SRC, YES1 | CA1 2920/4885CA2 1702/4885CA9 2127/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | CA1 861/4885CA2 573/4885CA9 53/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | CA1 4280/4885CA2 2972/4885CA9 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.